Citadel Advisors
CMTA

Citadel Advisors’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Citadel Advisors’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-181,262
Closed -$2.13M – 10248
2018
Q4 		$2.13M Buy
+181,262
New +$2.25M ﹤0.01% 4043
2018
Q1 		– Sell
-122,040
Closed -$2.32M – 9097
2017
Q4 		$2.32M Hold
122,040
– – ﹤0.01% 3434
2017
Q3 		$2.06M Buy
+122,040
New +$1.99M ﹤0.01% 3375

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $125M AUM 198.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Citadel Advisors's CMTA Position: Q1 2019 in Review

Citadel Advisors sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q1 2019, closing a stake of 181,262 shares — an estimated $2.13M sold.

Citadel Advisors first reported a position in CMTA in Q3 2017 and held it in 3 quarters. The position peaked at $2.32M in Q4 2017. 48 funds tracked by Wall St. Rank hold CMTA as of Q1 2019.

  • Citadel Advisors reported no remaining Clementia Pharmaceuticals Inc. position as of Q1 2019 after selling out during the quarter.
  • Citadel Advisors sold 181,262 Clementia Pharmaceuticals Inc. shares in Q1 2019, an estimated $2.13M.
  • Citadel Advisors first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 3 quarters.
  • Citadel Advisors's Clementia Pharmaceuticals Inc. position peaked at $2.32M in Q4 2017.
  • 48 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q1 2019.

Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.